Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced that the company will release its first quarter 2014 financial results on Tuesday, May 6, 2014, after the market closes. Sangamo Biosciences, Inc. (NASDAQ:SGMO) shares after opening at $13.71 moved to $14.00 on last trade day and at the end of the day closed at $13.84. Company price to sales ratio in past twelve months was calculated as 38.30 and price to cash ratio as 9.95. Sangamo Biosciences, Inc. (NASDAQ:SGMO) showed a negative weekly performance of -1.28%.
Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) revenue was down 29.8% compared to the same quarter last year. On average, analysts predict that Sucampo Pharmaceuticals will post $0.37 earnings per share for the current fiscal year. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) shares advanced 2.98% in last trading session and ended the day on $6.91. SCMP return on equity ratio is recorded as 6.90% and its return on assets is 2.50%. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) yearly performance is -27.34%.
On April 30, 2014, Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) reported sales of Alexion common stock made under a pre-arranged stock trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Dr. Bell’s currently existing pre-arranged stock trading plan adopted in accordance with Rule 10b5-1 for, among other things, estate and family financial planning, provide for the sale of up to an additional 230,280 shares of Alexion common stock. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares moved up 0.56% in last trading session and was closed at $158.20, while trading in range of $156.01 – $159.65. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) year to date (YTD) performance is 19.05%.
United Therapeutics Corporation (NASDAQ:UTHR) reported $1.77 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.65 by $0.12. The company had revenue of $289.40 million for the quarter, compared to the consensus estimate of $300.14 million. During the same quarter in the previous year, the company posted $1.19 earnings per share. The company’s revenue for the quarter was up 18.1% on a year-over-year basis. United Therapeutics Corporation (NASDAQ:UTHR) weekly performance is 6.81%. On last trading day company shares ended up $100.01. United Therapeutics Corporation (NASDAQ:UTHR) distance from 50-day simple moving average (SMA50) is 3.22%. Analysts mean target price for the company is $106.07.